MTAP and cholangiocarcinoma: Considering markers with experimental associations to targeted therapies, recent data on the trial of AMG-193 for MTAP-deleted BTC showed encouraging antitumor activity [35], while preliminary data for PARP-inhibitors in BRCA-associated CCA suggest the use of conducting a prospective basket trial [36].